|
Ethan Zohn’s Marathon Return
Access Hollywood In fact, Ethan was celebrating his one-year anniversary of being released from the hospital for his stem cell transplant, when he ran last year’s Boston Marathon. This was his first marathon after having undergone a transplant to battle his recurrence … |
Times of India |
Gut bacteria linked to alcoholic liver disease
Times of India “These findings provide first evidence for a causal role of gut microbiota in alcohol-induced inflammation,” said professor Frank Lammert, scientific committee member, European Association for the Study of the Liver. In the study, two groups of germ … Gut bacteria to blame for alcohol liver disease in some?India.Com Health |
|
Will Panasonic’s ‘hazard pay’ make a difference to air pollution in China?
The Guardian Cardiovascular disease, respiratory disease, lung and bladder cancers are some of the resulting illnesses. China’s premier, Li Keqiang, and his government have declared a war on pollution with several initiatives in … on behalf of Google), visited … |
Maintenance rituximab extended PFS, not OS in follicular lymphomaHealioPatients with follicular lymphoma who achieved stable disease with rituximab-based induction therapy demonstrated extended PFS and time to next treatment when they received maintena…
|
Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …
Jutia Group Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical … |
India.Com HealthKids who play outside less likely to get fatty liver diseaseIndia.Com Healthplaying kid Parents, let the kids play in the sun if you want them to keep non-alcoholic fatty liver disease (NAFLD) at bay as a research has confirmed links be…
|
Cambridge-US antibodies alliance
Business Weekly MacroGenics has two antibody technology platforms, a Dual-Affinity Re-Targeting (DART™) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimised antibodies with improved effector function. |
Long-Term Outcomes from Cytori Cell Therapy Trial for Heart Failure Published …MarketWatchSAN DIEGO, Apr 14, 2014 (BUSINESS WIRE) — Cytori Therapeutics (NASDAQ:CYTX) today announced publication of safety and efficacy data from a 36 month European cl…
|
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
The Herald | HeraldOnline.com (press release) Daclizumab high-yield process (DAC HYP) is in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at high levels on … Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …Jutia Group |
|
Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting
Benzinga … beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033). |